Susan Robson

1.2k total citations · 1 hit paper
17 papers, 826 citations indexed

About

Susan Robson is a scholar working on Pathology and Forensic Medicine, Genetics and Hematology. According to data from OpenAlex, Susan Robson has authored 17 papers receiving a total of 826 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pathology and Forensic Medicine, 6 papers in Genetics and 5 papers in Hematology. Recurrent topics in Susan Robson's work include Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Hemophilia Treatment and Research (5 papers). Susan Robson is often cited by papers focused on Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Hemophilia Treatment and Research (5 papers). Susan Robson collaborates with scholars based in Switzerland, Spain and Italy. Susan Robson's co-authors include Stephanie A. Amiel, Jane Speight, Carla Gianfrancesco, Lynn D. Newton, Simon Heller, Eileen Turner, Lindsay Oliver, Carolin Taylor, Sue Roberts and Peter James and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Annals of Oncology.

In The Last Decade

Susan Robson

15 papers receiving 773 citations

Hit Papers

Training in flexible, intensive insulin management to ena... 2002 2026 2010 2018 2002 100 200 300 400 500

Peers

Susan Robson
Björn Bolinder United States
Ben Whitelaw United Kingdom
Devin Steenkamp United States
Bithika Thompson United States
Jyotika K. Fernandes United States
T M Mack United States
F Bonńici South Africa
Shrikant Tamhane United States
Susan Robson
Citations per year, relative to Susan Robson Susan Robson (= 1×) peers Christopher Gilfillan

Countries citing papers authored by Susan Robson

Since Specialization
Citations

This map shows the geographic impact of Susan Robson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Robson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Robson more than expected).

Fields of papers citing papers by Susan Robson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Robson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Robson. The network helps show where Susan Robson may publish in the future.

Co-authorship network of co-authors of Susan Robson

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Robson. A scholar is included among the top collaborators of Susan Robson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Robson. Susan Robson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
2.
Castaman, Giancarlo, Flora Peyvandi, Johanna A. Kremer Hovinga, et al.. (2024). Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors. SHILAP Revista de lepidopterología. 8(1). e42–e54. 5 indexed citations
3.
Jiménez‐Yuste, Víctor, Flora Peyvandi, Robert Klamroth, et al.. (2022). Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY). Research and Practice in Thrombosis and Haemostasis. 6(8). e12837–e12837. 29 indexed citations
6.
Castaman, Giancarlo, et al.. (2021). Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A with FVIII Inhibitors: Final Analysis. Blood. 138(Supplement 1). 344–344. 6 indexed citations
7.
Bosch, Francesc, Guy Cantin, Agostino Cortelezzi, et al.. (2019). Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. Leukemia. 34(2). 441–450. 6 indexed citations
10.
Stilgenbauer, Stephan, Véronique Leblond, Robin Foà, et al.. (2018). Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. Leukemia. 32(8). 1778–1786. 20 indexed citations
11.
Leblond, Véronique, Melih Aktan, Caroline Dartigeas, et al.. (2018). Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. Haematologica. 103(11). 1889–1898. 13 indexed citations
13.
McArthur, Grant A., Michele Maio, Ana Arance, et al.. (2016). Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Annals of Oncology. 28(3). 634–641. 168 indexed citations
15.
Robson, Susan. (2010). Grasping the Nettle: Conflict and the Quaker Condition. 15(1). 67–83. 1 indexed citations
16.
Speight, Jane, Clare Bradley, Carla Gianfrancesco, et al.. (2005). Predicting outcomes in the dose adjustment for normal eating (DAFNE) trial. Deakin Research Online (Deakin University). 13(1). 89–89. 4 indexed citations
17.
Amiel, Stephanie A., Clare Bradley, Carla Gianfrancesco, et al.. (2002). Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes : dose adjustment for normal eating (DAFNE) randomised controlled trial. Deakin Research Online (Deakin University). 325(366). 746–749. 562 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026